DOTA-octreotide (TFA)

DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide. DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

12352209

Biochemical Assay Reagents; Radionuclide-Drug Conjugates (RDCs)

Antibody-drug Conjugate/ADC Related; Others

Cancer-programmed cell death

Cancer

99.30

O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](NC(CN2CCN(CCN(CCN(CC2)CC(O)=O)CC(O)=O)CC(O)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=CC=C4)N[C@@H]1CC5=CNC6=CC=CC=C56.O=C(O)C(F)(F)F

C67H93F3N14O19S2

1519.66

[1]Bodei L, et al., Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004 Jul;31 (7) :1038-46.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10273A/DOTA-Octreotide-TFA-SDS-MedChemExpress.pdf

Peptides

No Development Reported

RDC Peptide